Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Generic Entry into DPP-4 Class Poised to Accelerate in 2026
Several DPP-4 inhibitors are emerging as prime targets for additional generic listings in 2026, Jiho has learned, with copycat entries expected to broaden for products such as Januvia/Glactiv (sitagliptin) and Trazenta (linagliptin). According to industry sources, multiple generic makers are…
To read the full story
Related Article
- Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
- EquMet, Clenafin See Generic Entry in June Listing
June 12, 2025
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
- SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
BUSINESS
- Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
- Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer
January 23, 2026
- Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma
January 23, 2026
- Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…